Advanced searches left 3/3

Mg kg - DOAJ

Summarized by Plex Scholar
Last Updated: 23 April 2022

* If you want to update the article please login/register

Efficacy of 0.5 mg/kg of propofol at the end of anesthesia to reduce the incidence of emergence agitation in children undergoing general anesthesia with sevoflurane

This research looked at the safety of 0. 5 mg/kg propofol given at the end of anesthesia to minimize the incidence of EA in children undergoing general anesthesia. The propofol group's children were given propofol in a dose of 0. 5 mg/kg at the end of anesthesia, but those in the control group did not get any assistance at the time of anesthesia. Incidence of EA was 21. 9 percent in the propofol group relative to 51. 9 percent in the control group. Propofol group was longer than the control group, according to the Mean transfer time. One patient in the propofol group was found in one patient, but in the control group there were none. Five patients in the propofol group and eight patients in control were found in five patients and eight patients in control. Conclusion: With sevoflurane, administration of 0. 5 mg/kg of propofol at the end of anesthesia effectively reduces the risk of EA in children undergoing general anesthesia.

Source link: https://doi.org/10.4103/joacp.JOACP_257_19


An in vivo test to assess mefloquine 25 mg/kg for the treatment of uncomplicated falciparum malaria in Rondônia, Brazil

Plasmodium falciparum, a drug-resistant Plasmodium falciparum, is undermining malaria control attempts around the world. P. falciparum is treated with mefloquine at a dose of 15 mg/kg body weight in Brazil. Using MQ 25 mg/kg, we treated 50 patients aged one to 67 years who had acute, uncomplicated P falciparum malaria. Assessing evaluable patients, the day 42 cure rate was 40/42 [95. 2%].

Source link: https://doi.org/10.1590/S1413-86702006000400013


Risk factors for visceral leishmaniasis relapse in immunocompetent patients following treatment with 20 mg/kg liposomal amphotericin B (Ambisome) in Bihar, India.

BACKGROUND: A majority of all immunocompetent patients treated for visceral leishmaniasis have relapsed; however, the risk factors for relapse are not well understood. The aim of this research was to determine risk factors for VL relapse by investigating the characteristics of immunocompetent patients who relapsed following this therapy. FINDINGS: This is an observational retrospective cohort study of all VL patients treated by the MSF program from July 2007 to August 2012. In four doses of 5 mg/kg over 4-10 days, according to the severity of illness, the disease was treated in 8749 patients with VL. 1. 4% of the initial cure patients re-attended the program with parasitologically confirmed VL relapse, with a median time to relapse of 10. 1 months. CONCLUSIONS: This is the most significant cohort of VL patients treated with Ambient worldwide.

Source link: https://doi.org/10.1371/journal.pntd.0002536


Randomised controlled field study to evaluate the efficacy and clinical safety of a single 8 mg/kg injectable dose of marbofloxacin compared with one or two doses of 7.5 mg/kg injectable enrofloxacin for the treatment of Actinobacillus pleuropneumoniae infections in growing-fattening pigs in Europe

The study of 7. 5 mg/kg enrofloxacin in APP outbreaks in European farms was determined by an investigator. On day 0 or, 7. 5 mg/kg enrofloxacin intramuscular treatments were similarly divided among animals with respiratory disease clinical signs on day 0 and again on day 2, depending on clinical conditions. Following antibiotic therapy, animals improved rapidly and on day 7, clinical signs were absent or mild in all pigs and mean temperatures for each therapy were 39. 5 °C. On day 7, 81. 8 and 82. 2% respectively, with the primary efficacy criterion, animals cured, for marbofloxacin and enrofloxacin. Significantly more animals suffered concurrent disorders with enrofloxacin than marbofloxacin group P.

Source link: https://doi.org/10.1186/s40813-017-0057-2


Post Kala-Azar dermal leishmaniasis following treatment with 20 mg/kg liposomal amphotericin B (Ambisome) for primary visceral leishmaniasis in Bihar, India.

BACKGROUND: In India, the skin condition Post Kala-Azar Dermal Leishmaniasis accounts for up to 10% of patients treated for visceral leishmaniasis. The characteristics of patients who returned to the MSF-funded treatment program with PKDL were examined in this report. All patients received health information, including the danger and signs of PKDL development, as well as advice to return to the MSF program if these conditions persist. Slit-skin smear examination of symptoms that came from clinical history, appearance consistent with PKDL, and a first episode of VL among the 8311 patients under medical care were all reported as PKDL, which was later confirmed as PKDL. Those of the remaining cohort did not find any significant risk factors for PKDL among the VL patients treated with Ambisome who later developed PKDL. Following previous sodium stibogluconate therapy for VL, the time to establishing PKDL was much shorter with Ambisome than in a subgroup of patients presenting to the program with PKDL. CONCLUSIONS: In this large cohort of patients with VL in Bihar treated with 20 mg/kg Ambisome, the PKDL following therapy seems to be infrequent with no discernible risk factors. When advising patients treated with Ambient therapy regimens, consider the shorter median time to develop symptoms of PKDL compared to that after traditional VL therapy.

Source link: https://doi.org/10.1371/journal.pntd.0002611


Conscious Sedation Efficacy of 0.3 and 0.5 mg/kg Oral Midazolam for Three to Six Year-Old Uncooperative Children Undergoing Dental Treatment: A Clinical Trial

The aim of this review was to determine the safety of two dosages of oral midazolam for conscious sedation of children under dental care. Methods and Methods: 20 healthy children aged three to six years on a randomized double blind clinical trial were assessed, with either positively or positively biased Frankl's behavioral rating scales. Orally in the first session and 0. 3 million mg/kg oral midazolam plus 1 mg/kg hydroxyzine in the second session, and the 0. 6 mg/kg oral midazolam plus 1 mg/kg hydroxyzine in the upcoming session. The results showed that although administration of 0. 5 mg/kg oral midazolam was marginally higher to 0. 3 million mg/kg oral midazolam in terms of sedation safety, the differences were not significant. Conclusions: The overall success rate of the two drug combinations, namely 0. 5 mg/kg oral midazolam plus hydroxyzine and 0. 3 mg/kg oral midazolam plus hydroxyzine, was not significantly different for pediatric patients.

Source link: https://doaj.org/article/230f0e5016c34b6cbadb3b3b42b5a84c


Clinical efficacy and safety in patients treated with teicoplanin with a target trough concentration of 20 μg/mL using a regimen of 12 mg/kg for five doses within the initial 3 days

Abstract Background An teicoplanin containing a high dose of teicoplanin is recommended for the treatment of serious methicillin-resistant Staphylococcus aureus infections in patients. Despite the fact that the optimum Cmin of teicoplanin has been associated with improved clinical outcomes, reaching the target concentration is difficult. Patients with bacteremia/complicated MRSA infections were analyzed for clinical effectiveness. Result Overall, 512 patients were eligible, and 76 patients were tested for treatment toxicity. The percentage of patients meeting the target Cmin range by the enhanced regimen was significantly higher than that of the conventional regimen. There was no significant difference in the occurrence of adverse events between patients with or without a Cmin 20 g/mL. Conclusion A target Cmin 20 g/mL can be used in the early clinical trials during the treatment of difficult MRSA infections using teicoplanin for five doses within the first 3 days.

Source link: https://doi.org/10.1186/s40360-020-00424-3


Pharmacokinetic profiles of artesunate following multiple intravenous doses of 2, 4, and 8 mg/kg in healthy volunteers: Phase 1b study

Detailed information Severe malaria infections cause in over a million deaths each year, the majority of which were in children under the age of five years and living in sub-Saharan Africa. The Walter Reed Army Institute of Research has been constructing a novel good manufacturing practice injection of AS, which was approved by the U. S. FDA for study drug use and distribution by the CDC. Methods of In the Phase 1 clinical trial experiment, 24 healthy participants were assessed for varying doses of 2, 4, and 8 mg/kg daily as an anti-malarial drug. During the three days of therapy, drug levels showed no increase nor decline of the drug during the three days of treatment. In addition, the AS climbing multiple doses increased the AUC and C max values of AS and DHA.

Source link: https://doi.org/10.1186/1475-2875-11-255


Pharmacokinetic Studies in Elasmobranchs: Meloxicam Administered at 0.5 mg/kg Using Intravenous, Intramuscular, and Oral Routes to Nusehound Sharks (Scyliorhinus stellaris)

Eight healthy adult nursehound sharks were administered 0. 5 mg/kg intravenously, intramuscularly, and orally, with a minimum 4-week washout period between administrations. After the IM administration, Meloxicam-infused orally did not produce detectable levels in blood plasma, but average peak plasma concentration was 0. 38 0. 08 g/ml. Since IV injections, there was 11. 37 h/ml after IM injections, which increased to infinity. Meloxicam-assisted IM had a mean absolute bioavailability of 52. 2 percent versus 13. 29%. These results point to meloxicam as a promising drug to be used in elasmobranchs, raise dosage requirements, and show the need for more PK studies in sharks and rays.

Source link: https://doi.org/10.3389/fvets.2022.845555

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

Source Recommendations

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions